Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 10/2023

Inhalt (21 Artikel)

Open Access Review

Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer

Torhild Veen, Arezo Kanani, Dordi Lea, Kjetil Søreide

Open Access Research

Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens

Anup Y. Parikh, Robert Masi, Billel Gasmi, Ken-ichi Hanada, Maria Parkhurst, Jared Gartner, Sivasish Sindiri, Todd Prickett, Paul Robbins, Nikolaos Zacharakis, Mike Beshiri, Kathleen Kelly, Steven A. Rosenberg, James C. Yang

Research

Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics

Jiali Cheng, Yuyan Zhao, Hui Hu, Ling Tang, Yuhao Zeng, Xinyue Deng, Shengnan Ding, An-Yuan Guo, Qing Li, Xiaojian Zhu

Open Access Research

Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma

Jun Takei, Yuko Kamata, Toshihide Tanaka, Nei Fukasawa, Kazutaka Gomisawa, Mari Satake, Ryosuke Mori, Yohei Yamamoto, Tomoya Suzuki, Ayaka Oda, Mutsunori Murahashi, Takahiro Fukuda, Masayuki Shimoda, Yuichi Murayama, Yasuharu Akasaki

Research

CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer

Peiwei Yang, Fan Yu, Zheng Yao, Xu Ding, Hanmei Xu, Juan Zhang

Research

Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors

Fabrizio Nelli, Diana Giannarelli, Agnese Fabbri, Antonella Virtuoso, Julio Rodrigo Giron Berrios, Eleonora Marrucci, Cristina Fiore, Marta Schirripa, Carlo Signorelli, Mario Giovanni Chilelli, Francesca Primi, Valentina Panichi, Giuseppe Topini, Maria Assunta Silvestri, Enzo Maria Ruggeri

Research

SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function

Yixian Guo, Shouyu Ke, Feng Xie, Jieqiong Chen, Xu Liu, Zeyu Wang, Danhua Xu, Yanying Shen, Gang Zhao, Wenyi Zhao, Hong Lu

Open Access Research

Piper nigrum extract suppresses tumor growth and enhances the antitumor immune response in murine models of breast cancer and melanoma

Paola Lasso, Laura Rojas, Cindy Arévalo, Claudia Urueña, Natalia Murillo, Paula Nossa, Tito Sandoval, Luis Carlos Chitiva, Alfonso Barreto, Geison M. Costa, Susana Fiorentino

Research

Circadian pattern subtyping unveiling distinct immune landscapes in breast cancer patients for better immunotherapy

Siqi Xiong, Wenqiang Zhu, Liqing Wu, Tianmin Zhou, Wu Wang, Ouyang Zhang, Xiaoliang Xiong, Zhuoqi Liu, Daya Luo

Research

Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells

Marion Grard, Mohamed Idjellidaine, Atousa Arbabian, Camille Chatelain, Laurine Berland, Chantal Combredet, Soizic Dutoit, Sophie Deshayes, Virginie Dehame, Nathalie Labarrière, Delphine Fradin, Nicolas Boisgerault, Christophe Blanquart, Frédéric Tangy, Jean-François Fonteneau

Open Access Research

Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia

P. K. J. D. de Jonge, P. M. M. van Hauten, L. D. Janssen, A. L. de Goede, M. M. Berrien-Elliott, J. M. R. van der Meer, C. M. Mousset, M. W. H. Roeven, M. Foster, N. Blijlevens, W. Hobo, T. A. Fehniger, J. H. Jansen, N. P. M. Schaap, H. Dolstra

Open Access Research

Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events

Anna Jokimäki, Henna Hietala, Jasmiini Lemma, Hanna Karhapää, Anna Rintala, Jari-Pekka Kaikkonen, Kaisa Sunela, Eva Boman, Arja Jukkola, Satu Tiainen, Jan Seppälä, Aino Rönkä, Heikki Hakkarainen, Aarno Kärnä, Sanna Iivanainen, Jussi Koivunen, Päivi Auvinen, Micaela Hernberg, Milla Kuusisto, Tuomas Selander, Outi Kuittinen

Open Access Research

Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment

Maria del Mar Maldonado, Jeffrey Schlom, Duane H. Hamilton

Open Access Research

Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps

Luca Modestino, Leonardo Cristinziano, Marialuisa Trocchia, Annagioia Ventrici, Mariaelena Capone, Gabriele Madonna, Stefania Loffredo, Anne Lise Ferrara, Marilena Romanelli, Ester Simeone, Gilda Varricchi, Francesca Wanda Rossi, Amato de Paulis, Gianni Marone, Paolo Antonio Ascierto, Maria Rosaria Galdiero

Brief Report

Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resection

Julien Balzeau, Anindita Ravindran, Xin Wang, Jinal Maisuria, Anna Lucchesi, Hui Yao, Satoko Matsueda

Open Access Brief Report

Immune checkpoint inhibitor treatment of brain metastasis associated with a less invasive growth pattern, higher T-cell infiltration and raised tumor ADC on diffusion weighted MRI

Rasheed Zakaria, Michael D. Jenkinson, Mark Radon, Kumar Das, Harish Poptani, Nitika Rathi, Philip S. Rudland

Correction

Correction to: Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer

Jiannan Chen, Jianhua Hu, Lili Gu, Feng Ji, Fan Zhang, Miaomiao Zhang, Jun Li, Zhengliang Chen, Longwei Jiang, Yan Zhang, Ruifang Shi, Lihua Ma, Shaochang Jia, Ying Zhang, Qi Zhang, Junqing Liang, Shunyu Yao, Zhigang Hu, Zhigang Guo

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.